Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Common Equity (2019 - 2025)

Historic Common Equity for IDEAYA Biosciences (IDYA) over the last 7 years, with Q4 2025 value amounting to $1.0 billion.

  • IDEAYA Biosciences' Common Equity fell 341.91% to $1.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.0 billion, marking a year-over-year decrease of 341.91%. This contributed to the annual value of $1.0 billion for FY2025, which is 341.91% down from last year.
  • As of Q4 2025, IDEAYA Biosciences' Common Equity stood at $1.0 billion, which was down 341.91% from $1.1 billion recorded in Q3 2025.
  • Over the past 5 years, IDEAYA Biosciences' Common Equity peaked at $1.2 billion during Q3 2024, and registered a low of $233.1 million during Q1 2021.
  • Its 5-year average for Common Equity is $626.9 million, with a median of $504.8 million in 2023.
  • Per our database at Business Quant, IDEAYA Biosciences' Common Equity surged by 18019.26% in 2024 and then tumbled by 748.75% in 2025.
  • Over the past 5 years, IDEAYA Biosciences' Common Equity (Quarter) stood at $301.5 million in 2021, then grew by 15.9% to $349.5 million in 2022, then skyrocketed by 77.73% to $621.1 million in 2023, then surged by 70.53% to $1.1 billion in 2024, then dropped by 3.42% to $1.0 billion in 2025.
  • Its Common Equity stands at $1.0 billion for Q4 2025, versus $1.1 billion for Q3 2025 and $959.7 million for Q2 2025.